

**TZF POLFA S.A.**  
**200 YEARS OF EXPERIENCE**  
**IN PHARMACEUTICAL INDUSTRY**

# OUR COMPANY

Established in 1823, TZF Polfa S.A. has been steadfastly committed to providing generic pharmaceutical solutions, using our rich history, **one of the oldest pharmaceutical company in Europe**, to drive innovation and meet the dynamic needs of the healthcare industry.

By manufacturing both active pharmaceutical ingredients and finished dosage forms (solid dosage forms, injectables, aerosols, and gels), we provide our customers with extensive expertise in cutting-edge pharmaceutical solutions in different therapy and production areas. The quality of our products has been confirmed by the obtained GMP certificates.






PRESCRIPTION  
MEDICINES



DERMOCOSMETICS



MEDICAL FACE MASKS



OTC MEDICINES



DIETARY  
SUPPLEMENTS



PHARMACEUTICAL  
SUBSTANCES API



OVER 200 YEARS  
OF TRADITION



1 000 PEOPLE  
ON BOARD



30 RESEARCH AND  
DEVELOPMENT PROJECTS



11 PRODUCTION  
BRANCHES



25 MILLION  
PACKAGES A YEAR



130 FORMS  
AND DOSES



60 INTERNATIONAL  
MARKETS




4 CONTINENTS:  
ASIA, AFRICA, EUROPE,  
SOUTH AMERICA

# LEADER IN THE INSTITUTIONAL AND RETAIL MARKET



WE MAKE A DIFFERENCE



\*Data source: IQVIA YTD 06,2024 data units for institutional and retail market

# TZF POLFA ENSURES THE DRUG SAFETY



Leading manufacturer providing Polish hospitals with key antibiotics and CNS drugs. Poland's only manufacturer of penicillin drugs for adults and children. Poland's only manufacturer of the drug of last resort DoLR (colistin) for the treatment of sepsis.



Manufacturer of 10% of the critical drugs listed in the EU critical medicines list.



Collaboration with the Ministry of Health and the Governmental Strategic Reserves Agency to ensure the continuous availability of essential medicines, regardless of financial and logistical challenges.

# SALES NETWORK

We supply hospitals and pharmacies through the network of wholesalers across the country.

Our medical representatives reach a diverse group of healthcare professionals.



GENERAL PRACTITIONERS



PAEDIATRICIANS



LARYNGOLOGIST



PSYCHIATRIST




DERMATOLOGIST



# MANUFACTURING TECHNICAL CAPABILITIES



WE MAKE A DIFFERENCE



# PHARMACEUTICAL MANUFACTURING FACILITIES – CMO/CDMO



Center for the Development and Production of Highly Active Drugs



New Ampules Filling Department



Sterile Dry Filling Facility

**TZF POLFA is a significant player in the international arena offering our own products and partnership for: CMO/CDMO.**



WE MAKE A DIFFERENCE

# CENTER FOR THE DEVELOPMENT AND PRODUCTION OF HIGHLY ACTIVE DRUGS

- Greenfield construction of total area c.a. **12 000 m<sup>2</sup>** and cubature of **75 000 m<sup>3</sup>**, **4 floors**.
- Two separate production lines, dedicated to sterile manufacturing also toxic compounds up to **OEB 5**.
- Aseptic production condition in isolator technology, SUS possible.
- Separate R&D and QC laboratory space (high potency product).
- Facility compliant with cGMP (EU), FDA, EAEU.



# COMBO LINE

Manufacturing of

- ✓ **liquid filled vials**, dosing accuracy < 1%, vials 2R – 50R;
- ✓ **powder filled vials** (80 to 1000 mg/vial), vials 10R – 50R;
- ✓ **Lyophilizates** (Lio shelves area 15 m<sup>2</sup>), vials 2R – 50R.

All in different volumes and variety of presentations.

- Isolator technology Class A, surrounded by class C.
- Possibility of product inertisation (nitrogen, argon).
- 100% of filling IPC.
- Aseptic filling or terminal sterilization possible.
- CIP/SIP in place or SUS preparation conditions possible.

Manufacturing capabilities up to **20 M vials/year**.




# HIGH-TECH HIGH-CONTAINMENT ROBOTIC LINE

- Operation with compounds defined as **OEB 5** class.
- Manufacturing of:
  - ✓ **liquid filled vials**,  
vials 2R – 50R;
  - ✓ **liquid filled syringes**,  
PFS 0,5 ml – 5,0 ml;
  - ✓ **lyophilisates** (Lio shelves area 5 m<sup>2</sup>),  
vials 2R – 50R.


All in different volumes and variety of forms.

Manufacturing capabilities up to **6 M packaging/year**.



# NEW AMPULES FILLING FACILITY

- Manufacturing of **liquid filled ampules**, sizes 2 ml and 5 ml, other sizes available upon special request.
- oRABS technology Class A, surrounded by class B
- 100% of filling IPC.
- Aseptic filling or terminal sterilization.
- Manufacturing capabilities up to **30 M ampules/year**.
- Toxic application possible up to **OEB 4**.
- Process inertisation by N2 purging.



# NEW AMPULES FILLING FACILITY

- Automatic visual inspection machine.
- Transparent and amber ampules.
- Validated for **2 ml and 5 ml ampules.**
- Location: Warsaw.



# STERILE DRY FILLING FACILITY

- Manufacturing of **powder filled vials** (80 to 3000 mg/vial), vials 20H – 200H.
- Isolator technology Class A, surrounded by class C.
- 100% of filling IPC.
- Aseptic filling.
- CIP/SIP in place.
- Manufacturing capabilities up to **6 M vials/year**.
- Toxic application possible up to **OEB5**.
- Location: Lodz.






WE ARE PRESENT

ON

**60 MARKETS**



**Your idea. Our expertise.**  
**One journey.**